Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Expands High-Content Screening Offerings with Two Pacts

NEW YORK (GenomeWeb News) – GE Healthcare has signed agreements with two separate firms intended to expand its offerings in the high-content cell screening field, the firm announced today.
The first pact is with Process Analysis and Automation, under which PAA will provide automated hardware and software for GE Healthcare’s IN Cell Analyzer and LEADseeker platforms.
Through the second agreement, with MatriCal, GE Healthcare will now be able to offer 96-well and 384-well, flat glass-bottom microwell plates “at a competitive rate.” GE said MatriCal’s plates provide low autofluorescence, evenness of plate surface, and optimum optical viewing surface for cell-based assays.
GE announced the alliances at the CHI High Content Analysis meeting taking place this week in San Francisco.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.